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Abstract 
The aim of this paper is to estimate the return to the UK from health sector R&D 
drawing on the value of life methodology and the work by Murphy and Topel (2003). 
While acknowledging the caveats arising in making such calculations, not least the 
lack of consideration given to spillover effects from R&D undertaken elsewhere, this 
method is useful in at least attempting to initiate a quantification of the returns to 
medical R&D. Using life cycle consumption information, value of life estimates for 
the UK and changes in survival probabilities, the value of improved longevity in the 
UK over the years 1970-2000 is estimated at approximately £2.84 trillion, or £2.58 
trillion after netting out health care expenditure. This is approximately double the 
current yearly GDP of the UK. The estimated gains are greatest for the period 1980-
1990. Given that the UK spends less than 0.5% of its GDP per annum (approximating 
£0.2 trillion over the 30-year period) on medical R&D, while clearly not all the gains 
in longevity can be attributed solely to medical R&D, the inference is that the returns 
to such investments are substantial. While such gains might be considered an upper 
estimate, given that the approach attributes all gains in life expectancy as a return to 
medical R&D over the period, gains in morbidity attributable to improved health 
delivery arising from medical R&D are not included in the estimate thus imparting a 
downward bias on the estimates as well as highlighting an obvious extension to this 
research. 
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1. Introduction 
Continuing research and development is an important contributory factor to economic 
growth in any country. In 2001 the UK spent approximately 1.8% of GDP (£17.5 
billion) on research. In 2004, as part of the UK government’s plans to increase the 
country’s productivity, the government announced a 10-year strategy committing an 
increase in R&D funding to 2.5% of GDP by 2014 with an average increase over the 
next 3-years of 5.8%. Medical research remains a major contributor to general UK 
R&D and, in particular is a major public sector activity in the UK. The absolute levels 
of medical research in the UK are considerable. Table 1 gives a breakdown of UK 
R&D medical research expenditure by different funding board category from the year 
1997/98 up to 2002/03 for the public sector (including non-profit making, charitable 
foundations). UK medical research by public bodies approached £2.5 billion in 
2002/03. This public funding was approximately matched by UK pharmaceutical 
company R&D expenditure of £2.9 billion, of which approximately £250m is 
channelled through university research, to give a total annual investment of research 
funds in the UK health care sector of approximately £5.3 billion.1 Internationally, this 
makes the UK one of the largest contributors to medical research across the world. 
 
With the government committed to increasing R&D expenditure, health sector R&D 
is also set to grow. Therefore, it is not surprising that increasing attention is being 
focused on the returns from such funding. At least three levels of returns to medical 
R&D can be distinguished: returns specified in terms of scientific knowledge; returns 
specified in terms of health benefits; and returns specified in terms of wider economic 
returns. The aim of this paper is to outline monetary estimates of the economic value 
of changes in UK life expectancy over the period 1970 to 2000, by drawing on a 
methodology proposed by Murphy and Topel (2003). In doing so this represents a 
first stage in attempting to attribute gains in longevity as a return to medical R&D. It 
is a first step for  
 
a number of reasons: first, attributing all gains in longevity to R&D is not just heroic, 
it is obviously wrong. It is bound to overestimate a dimension of the gain. That said, 
                                                 
1 The US scientific base of billion is used to represent 109 and trillion is used to represent 1012. 
Traditional British use would denote 1012 as a billion. Harold Wilson, the Prime Minister of the UK, 
announced in 1974 that government statistics would conform to US standard usage with the term 
billion taken to mean 109 , and 1012 taken to be a trillion. It would appear he therefore devalued more 
than the pound sterling. 
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gains in terms of morbidity are not considered at all and the attribution of return to 
medical R&D will be tempered in this respect. One justification for pursuing the 
approach is that it indicates the potential size of the return to medical R&D in a 
quantifiable manner. That said no precise value of the return is highlighted for a 
number of reasons, both conceptual and practical. 
 
Table 1. Total Health Research and Development Expenditure (excluding profit 
making sector). £ Millions 
 
  1998/99 1999/00 2000/01 2001/02  2002/03 
Higer Education Funding COuncils 
HEFCE 219.4 238.3 243.7 249.9 255.5 
SHEFC 26.7 27.1 27.5 28.6 34 
HEFCW 8.1 8.7 9 10.6 9.2 
DEL/NI 1.8 1.9 2.1 2.3 3.2 
Research Councils 
BBSRC 89.4 94.1 98.7 93.1 103.4 
MRC 310 339.5 362.9 423.5 434.5 
Civil Departments 
NHS/DOH 420 434 448 475 506 
DFID 47.6 81.2 123.7 99.3 168.3 
Private Non-Profit 
AMRC 418 544 632 594 660 
WELLCOME 173 279 348 273 345 
TOTAL 1,714.0 2,047.8 2,295.6 2,249.3 2,519.1 
 
As an economic commodity R&D has a number of characteristics that may result in 
general underinvestment. In particular, uncertainty and the public good nature of the 
commodity, where once knowledge has been released it becomes consumable by all, 
make the return to R&D high risk. Notwithstanding the inherently risky nature of 
R&D it has long been recognised that it is notoriously difficult to estimate the return 
to R&D (Arrow, 1962). As with most service-based industries, the problem of 
estimating returns to R&D is intensified as specific returns to medical care research 
are difficult to capture.  
 
Many innovations come in the form of changes in process or techniques that can not 
be patented, making it difficult to for the private investor to capture the return. This 
return to R&D should be set in terms of increases to economic welfare. The difficulty 
becomes how to measure this increase in economic welfare. R&D expenditure, even if 
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the area of concern is limited to the health care sector, is heterogeneous. By definition 
there is both research and development; moreover research may be classified as basic 
or applied. Various types of spending on the diverse characteristics of R&D will result 
in different types of additions to economic welfare. In the area of health care the 
social benefit is especially difficult to quantify. 
 
As well as conceptual problems there are practical concerns. Stoneman (2001) 
identifies at least three. First, the issue of counterfactual evidence ought to be 
addressed. The measurement of R&D policy requires evidence on what would have 
occurred if the policy had not been undertaken. In the case of R&D in the health care 
sector the obvious question is, given the impact of lifestyle and environment on 
health, what gains would have been achieved even without technical advances in 
medical care? Second, how should spillover effects, either the medical advances 
achieved elsewhere the gains from which are realised in the UK or the returns 
achieved in other settings from UK R&D, be accounted for? The public good nature 
of research, essentially through the dissemination of knowledge, makes it most 
susceptible to these external effects. There are also direct spillover effects gained from 
medicines developed and imported from abroad. While trade balances in 
pharmaceuticals do not map the spillover gains they do give an indication of potential 
importance of such effects; the UK for example exported £12.3 billion in 
pharmaceutical trade and imported £8.6 billion in 2004.  Third, the time span over 
which the effects should be measured also presents an issue. For example, health 
benefits may have an effect over generations. 
 
Despite the acknowledgement of such conceptual and practical issues, a recent paper 
by Murphy and Topel (2001) attempted to indicate the value of medical R&D to 
society through considering the impact that medical research has had on health, 
specifically  
 
mortality rates by age and sex, by estimating the monetary value that society places on 
the health gains achieved through increased longevity. The Murphy and Topel (op. 
cite.) paper was based on US data and thus estimates returns to US medical research. 
This paper draws on the methodology used by Murphy and Topel to give broad 
estimates of the magnitude of the return to UK medical research over the period 1970 
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to 2000 as based on the value of longevity achieved over this period. To do so 
assumptions similar to those in the Murphy and Topel study are made but UK data are 
used to indicate UK specific values of the return to medical R&D. 
 
One practical issue, as noted above, is the choice of timeframe. The health of the UK 
population has been improving markedly for a long period. Crude mortality rates for 
various diseases exhibit marked declines as shown by Figure 1 with consequent 
improvement in life expectancy. The most remarkable decline has been with respect 
to circulatory diseases, even though this remains the most common cause of death. 
Cancers are now the second most common cause of death in England and Wales, but 
even here there has been a slight decline in mortality rates over the last 10-years. It is 
undoubtedly true, for example that major pharmacological and surgical innovations, 
including the introduction of beta-blockers, ACE inhibitors, statins and diuretics as 
well as the introduction of angioplasty and stenting have had a marked impact on 
morbidity and mortality arising from circulatory diseases, but so too has the change in 
smoking habits. While undoubtedly arbitrary, 1970 is taken as the starting point for 
the analysis as it was during this decade that the first major treatment improvements 
with respect to heart disease were introduced. 
 
Figure 1. Common causes of death in England and Wales. Mortality rates 1911-2003 
 
 
Source: ONS 
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The paper is structured as follows. The next section discusses the methodological 
approach used to value changes in life expectancy in some detail. This is then 
followed by the basic results gained from the UK calculation. A discussion of 
limitations and potential improvements on the approach then follow. 
 
2. Methods 
The basic approach adopted by Murphy and Topel draws on an established literature 
suggesting that estimates of individuals’ willingness-to-pay (WTP) for reductions in 
mortality risks can be converted into an estimate of the value of a statistical life 
(Viscusi and Aldy, 2003). The fundamental idea is to assume that individuals would 
be willing to pay a monetary sum to reduce the risk of mortality. Estimates of the 
values attached to reductions in these risk levels extrapolate to an estimate of the 
value of a (statistical) life. This literature has a long history (Mishan, 1971). 
 
The formulation of the WTP for changes in the risk of dying is premised on the utility 
gained from wealth under different mortality risks. The concept of the value of a 
statistical life has been traditionally formulated in this manner with much empirical 
work, based largely in the USA, deriving values of the WTP for changes in the risk of 
death from observed differences in the income levels associated with risky(in terms of 
risk of death) and low risk occupations (Viscusi and Aldy, 2003). The associated 
empirical literature produces a range of estimates that involve implicit tradeoffs 
between mortality risk and wealth, essentially calculating the average marginal rate of 
substitution of wealth for risk, in a number of different circumstances. Most of these 
estimates have been based on the so-called compensating variation required by 
individuals to undertake risky tasks in the labour market. The extension to calibration 
with wealth is obvious. The formulation can however be changed to calibrate WTP 
for changes in mortality risk with utility levels, (i.e. measures of individual welfare), 
derived from consumption and leisure activities with the basic idea being that 
individuals derive utility not from wealth per se but from the use of wealth in 
consumption and leisure activities. Again this calibration can be performed for 
different ages and across different time periods. The approach adopted below extends 
this empirical literature through an adaptation based on Murphy and Topel (2003), 
utilising the calibration of WTP for reduced mortality risk with the utility derived 
from lifetime consumption and leisure. 
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 Such WTP estimates were used as an essential component of the Murphy and Topel 
calculation. It is well recognised however that there are limitations to this approach. 
The most obvious drawback is that such estimates are based on implied trade-offs 
gained from individuals of working age. It is also accepted that future life expectancy 
will affect the value of a statistical life. Age obviously affects the duration of life at 
risk but may also be correlated with other factors, including changes in preferences, 
especially about exposing oneself to and taking risks, which will affect an individuals’ 
WTP to for changes in survival probability. Moreover, non-pecuniary aspects of work 
will be omitted from such labour market based calculations. Injury risk may also be 
correlated with mortality risk and the implied estimated gained from labour market 
studies may be biased because of the lack of inclusion of this injury risk. Indeed even 
individual characteristics, such as clumsiness, may affect the estimates gained from 
implicit trade-offs based on labour market studies. Moreover, given the expected 
positive income elasticity with respect to the value of risks to an individual’s life, it 
might be predicted that estimates gained from studies conducted in the USA would 
have a tendency to be higher than in other countries, given the higher average 
earnings of workers in the USA compared to other countries. Indeed a recent review 
of the literature on the value of a statistical life found that UK studies estimate 
compensating differentials which are “implausibly large” and of the order of 10 
percent of wage income compared to the 1 to 2 percent of wages found for the USA 
(Viscusi and Aldy, 2003). 
 
Given these implausible values and the fact that the UK literature on the WTP for 
reduction in mortality risk literature has been dominated by a related but different 
methodology, an altered approach to WTP forms the basis of the analysis presented 
here. UK measures of the WTP for changes in mortality risk, and subsequent 
valuation of a statistical life, have been based upon contingent valuation studies that 
use direct questionnaire based methods to elicit explicit trade-offs between wealth and 
safety. The resultant monetary values of individuals’ WTP to reduce the risk of 
fatalities, accidents and morbidity are used by UK governmental departments to assist 
in the calculation of the costs and benefits of various public sector funded projects. 
Thus, as reported by Chilton et al (2002) the value of the prevention of a statistical 
fatality used by the UK Department of Environment, Transport and Regions (DETR) 
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in evaluating public sector road projects has been based on questionnaire based 
preference elicitation techniques to calculate the value individuals place on safety 
which is then used to estimate the marginal value of a change in the probability of 
survival. The current value of a statistical life used by the DETR as based on 
preference elicitation techniques is £1.14 million (2000 prices).2
 
Recent attempts to re-estimate these values in the UK have focused on relative 
valuations of the WTP for reduction in mortality risk in different settings (Chilton et 
al, 2002). This recent work recognises that various aspects of individual decisions 
may affect the preference based valuations of risk of death when these risks are 
assessed in different contexts. Thus issues of control over the circumstance, past 
experience, knowledge, fear, dread and expectation could also affect the elicited 
valuation.3 That said, most empirical work suggests that individual estimates of the 
value of a statistical life do not significantly vary across different settings (Chilton et 
al, 2002). The relative valuation approach also recognises that small absolute risk 
values, as used in calculations where circumstances were such that low absolute risk 
values formed the basis of the calculation as death was rare in the examples used, may 
lead to error in the direct estimation of willingness-to-pay (WTP) values for changes 
in survival probability. Typically such estimates of WTP are calculated by dividing 
mean reported WTP estimates for a given reduction by the risk reduction itself. Where 
this is the case, even small miscalculation of the WTP response by respondents will 
lead to over-estimation of the WTP. The relative value approach uses an estimated 
relative value ratio of, for example, risk of death from road and rail travel in 
conjunction with the (relatively high) absolute risk of death from road travel to 
overcome this. This approach is similar to the “person trade-off” methodology 
adopted by Nord (1992) and suggested as a means of estimating the relative values of 
specific health care interventions. 
 
Using as a base the estimated value of a statistical life set at £1.14 million as used by 
the UK Department of Environment, Transport and Regions, the analysis continues by 
                                                 
2 eftec (2004), in a review for the UK Department of Environment, Food and Rural Affairs, states that 
the value of life estimates are largely invariant to context and a consensus figure of £1 to £1.2 million 
emerges from a review of stated preference studies. One area where there is considerable variation 
arises when individuals are asked questions relating to death from specific disease, most notable 
cancer, where the returned estimates are approximately double this figure. 
3 See footnote 2 above for discussion. 
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assuming that medical research leads to further improvement in individual survival 
probabilities that may be given a monetarised value based on this estimated value of a 
statistical life.4 The basic approach sees an individual trying to maximise their own 
welfare through enjoying consumption and non-market activities over a healthy 
lifetime; individuals derive utility from consumption and leisure the benefits from 
which may be estimated over their lifetime in terms of a discounted monetary 
equivalent sum. The estimation of the value of a gain in survival time is calculated by 
ignoring non-healthy time; that is by assuming that a gain in life expectancy is of 
value regardless of how healthy the individual is with improved life expectancy. To 
the extent that an individual will pay more for improved health as well as life 
expectancy the estimated value of a gain in survival time is therefore conservative. 
Any WTP for a gain in survival time must then be equal to the utility gains enjoyed 
from improved life expectancy; the marginal costs defined in terms of WTP must 
equal the marginal benefits defined in terms of utility gain. Thus an estimated WTP 
for a stated reduction in annual mortality risk, taken from the UK literature based on 
the normalised value of a statistical life, is set equal to full lifetime consumption, 
amended for any surplus gained from any preference for consumption at given points 
in an individual’s life cycle, further weighted by changes in life expectancy. That is, 
the marginal cost in terms of WTP for additional survival is equal to the marginal 
benefit in terms of additional utility gained from additional life expectancy controlling 
for consumption and saving preferences over an individual’s lifetime. 
 
A standard individual lifetime utility maximising model is then the starting point for 
the Murphy and Topel model. This can be represented, using their notation, as: 
 
∫∞ −=
0
)())(),(()( dttStltcutHeV pt       [1] 
 
Where V is the expected lifetime utility of an individual and is given as the discounted 
gains (with the discounting factor given as ) derived from consumption  and 
non-market  activities enjoyed over healthy  survival time . Ignoring 
pte− )(tc
)(tl )(tH )(tS
                                                 
4 The value of a statistical life is normally gained from contingent valuation questions which relate to 
questions based on risks in mortality around 1/10,000 or 1/100,000 (Jones-Lee et al, 1995). So the 
value of a statistical life can be re-based into a change in a small risk. In our case a change in mortality 
risk of 1/10,000 is used. 
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the health status aspects of changes in life expectancy and assuming that life cycle 
preferences can be modelled as a given surplus of present consumption over lifetime 
consumption then the WTP for improved longevity may be expressed as: 
 
∫
∞
− Δ=
0
)()( dttStCedV F
rtθμ        [2] 
 
where μ
dV  is the WTP for improved longevity which is equal to the discounted (at a 
constant rate r ) value of the additional survival gains )(tSΔ  valued in terms of the 
life time consumption of market and non-market activities (the monetary value of 
consumption and leisure activities ( )) weighted by the value of life cycle 
preferences to the individual (
)(tCF
θ ) . This general equation can be evaluated at different 
ages and set equal to a pre-defined WTP for a given reduction in the probability of 
death ( λ)(aW ) to give the WTP for improved longevity at age a (
)(
)(
a
adV
μ ) as: 
 
∫∞ −− ==
a
F
atr aWdt
aS
tStCe
a
adV )(
)(
)()(
)(
)( )( λθλμ      [3] 
 
 
where all terms are as before with the exception that the additional survival gain is 
from age  and the change in longevity is defined as a dt
aS
tS
)(
)(  and λ is the pre-
specified magnitude of the reduction in the risk of death as defined previously. 
 
Assuming that the improvement in longevity is attributable to both improvements in 
medical knowledge and health care itself then the gain to an individual who has 
survived to age  from improvements in medical knowledge through medical 
research, can be given as: 
a
 
dttCZRtaSeRaV FR
a
atr
R )(),,,(),(
)( θ∫∞ −−=      [4] 
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where is the value of the gain in medical research ),( RaVR R  to an individual aged 
,  is the gain in longevity for an individual aged a  attributable to 
medical research 
a ),,,( ZRtaSR
R  and health care Z , and all other terms are as before. A discrete 
version of (4) amenable to empirical investigation is given as: 
 
[∫
∞
−− −=−
a
F
atr dttStStCeVV )()()( 12
)(
12 θ ]       [5] 
 
where and are two survival functions which individuals can switch across 
and assuming > encompasses the gains in longevity. 
)(1 tS )(2 tS
)(2 tS )(1 tS
 
Finally this value of increased longevity can be aggregated from the individual level 
to the population level across all age groups such that the population gains are given 
as: 
 
∑
=
=
T
a
RR RaVtaNtV
0
),(),()(        [6] 
 
where  is the number of individuals of age  at a given time , and  is 
given by equation [4] . 
),( taN a t RV
 
This basic methodological framework draws heavily on and replicates the Murphy 
and Topel (2003) approach to allow an indication of the possible value of medical 
research to any given population calculated through the WTP for a reduction in 
mortality risk and the utility benefits gained from increased longevity. 
 
Of course a number of assumptions have been made to make this method amenable to 
empirical investigation. First, a time period has to be specified. This paper considers 
the period 1970 to 2000. This period is arbitrary but coincides with large mortality 
declines in the UK population from various diseases, most notably coronary heart 
disease. Second, gains in health from medical research are calculated having taken 
account only any contemporaneous gains attributable to health care. Any health gains 
from lagged health care effects, changes in individual behaviour or changes in 
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environmental conditions are not estimated with the possible inference that there is 
over-estimation of the benefits from medical research. On the other hand, in 
compensation, any health gains attributable to medical research resulting in changes 
in morbidity and quality of life are not included in the calculation/estimate thereby 
underestimating the return to medical research. 
 
3. Empirical Results 
The estimates of the WTP are derived for 3 sub-periods, (1970-1980; 1980-1990; 
1990-2000), and then aggregated for the full period 1970-2000. To gain empirical 
estimates the investigation proceeds as follows. First, a value of the WTP for a given 
reduction in the probability of death is specified which to enable estimation of the 
parameter θ  from equation [3] given above and repeated below 
 
∫∞ −− ==
a
F
atr aWdt
aS
tStCe
a
adV )(
)(
)()(
)(
)( )( λθλμ       
 
As Murphy and Topel note,  is commonly referred to as the “value of a 
statistical life” when 
)(aW
λ  is set equal to 1. However empirical estimates of the WTP for 
changes in survival probability are normally gained when λ  is set to a value less than 
1 or when individuals are requested to provide information on WTP for values of λ  
less than 1. The current value of a statistical life used by the UK Department of 
Transport as based on preference elicitation techniques £1.14 million (2000 prices) 
and this forms the basic input into the equation above. 
 
The calculation also requires information on life cycle consumption, . This is 
gained, as in the Murphy and Topel study, through a proxy based on male lifetime 
earnings. This was taken from an ONS/DTI study on individual income (ONS, 2004) 
which reported the median income by age band for men and women in 2003/04. The 
relevant figures, based on net median weekly income for men, are reported in Table 2 
and taken as a proxy for lifetime consumption
)(tCF
5. Finally a discount rate of 3.5% is 
used as recommended by the UK Treasury for the discounting of health benefits.  
                                                 
5 This follows the same assumption as Murphy and Topel that full income is proportional to male 
lifetime income profile and is captured by a representative earnings profile. The earnings profile is 
extended to those younger than 16 by assuming their median “income” is the same as for the 16-19 
year olds.  
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Table 2 
Age Annual Median Income, Males 2003 
16-19 £5,096  
20-24 £10,712  
25-30 £17,160  
30-34 £20,540  
35-39 £21,996  
40-44 £21,944  
45-49 £21,840  
50-54 £19,188  
55-59 £17,784  
60-64 £13,104  
65-69 £11,128  
70-74 £10,296  
75-79 £9,308  
80-84 £8,632  
85+ £8,736  
 
 
Substitution of the relevant values into equation [3] and solving for θ , the weight 
allocated by individuals to life-cycle consumption relative to current consumption, 
results in an estimate of 2.89 for this parameter.6 Figure 2 reports the resultant life 
cycle profile for an individual’s WTP for a 1/10,000 reduction in contemporaneous 
mortality risk for men and women based on the value of a statistical life set at £1.14 
million (the y-axis measures WTP in £s; the x-axis measures age). This life cycle 
estimate of full income allows calculation of the monetary value of further reductions 
in mortality risk attributable to R&D. 
 
This calculation of the WTP for changes in survival probability at the individual level 
can be used to consider the value associated with changes in life expectancy 
attributable to medical research across all age groups. Following Murphy and Topel 
the increased value in life expectancy is estimated through the following equation, 
with the definitions as given above by equation [5] reproduced below  
 
[∫
∞
−− −=−
a
F
atr dttStStCeVV )()()( 12
)(
12 θ ]
                                                
  
 
 
6 This is remarkably similar to Murphy and Topel’s estimate of 2.9 in their calculations. 
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Figure 2 Value of a reduction of a 1/10,000 risk of mortality by age (£2000 prices) 
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The value of increased longevity can be aggregated to the population level such that 
the population gains are given as: 
 
∑
=
=
T
a
RR RaVtaNtV
0
),(),()(        [7] 
 
To implement these calculations the value of θ  is equal to 2.89 as estimated 
previously and the two survivor functions and  relate to the years 1970 and 
1980, 1980 and 1990, and 1990 and 2000 in respective calculations. For all 
calculations the base year population is taken from the year 2000 and the discount rate 
is 3.5% per year. 
)(1 tS )(2 tS
 
Figures 3 and 4 show the results in terms of the estimated per capita gains in monetary 
terms that are associated with improved UK survival functions for the periods 1970-
1980; 1980-1990; 1990-2000. The graphs cumulate the per capita gains in each period 
so that the total height of the graph reports the total per capita gains in reduced 
mortality over the whole period 1970-2000. The monetary measurement of the gains 
in individual survival over the period are substantial. Improvements in life expectancy 
over the total period peak for men around the age of 60 at approximately £90,000, 
while for women they peak at around £60,000 at 65 years of age.  
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Figure 3 Value of monetary gains from increased survival probability: males 
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Figure 4. Value of monetary gains from increased survival probability: females 
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Table 3 reports the gains in economic welfare from improved survival for the periods 
1970-1980; 1980-1990; 1990-2000 and over the whole period 1970-2000 and forms 
the basic results. The Table shows the gains by age group for the various sub-periods 
for males and females. The table also shows the aggregate gains. Over the whole 
period the gains are substantial at approximately £2.84 trillion. This is approximately 
double the current yearly GDP of the UK. The gains are greatest for the period 1980-
1990. 
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Table 3 Economic gains from reduction in mortality by age 
 
Table 3a 
Males Aggregate Gains (£, 2000 prices) 
Agegroup 1970-1980 1980-1990 1990-2000 
Birth £3,610,000,000 £3,010,000,000 £2,480,000,000 
1-4 £16,300,000,000 £13,700,000,000 £11,300,000,000 
5-9 £24,200,000,000 £20,600,000,000 £17,200,000,000 
10-14 £27,800,000,000 £23,900,000,000 £20,300,000,000 
15-19 £29,500,000,000 £25,700,000,000 £22,000,000,000 
20-24 £31,200,000,000 £27,600,000,000 £23,800,000,000 
25-29 £39,000,000,000 £35,400,000,000 £30,900,000,000 
30-34 £46,900,000,000 £44,400,000,000 £39,300,000,000 
35-39 £49,500,000,000 £49,900,000,000 £44,700,000,000 
40-44 £45,100,000,000 £49,000,000,000 £44,500,000,000 
45-49 £41,800,000,000 £49,600,000,000 £45,800,000,000 
50-54 £44,400,000,000 £58,000,000,000 £55,500,000,000 
55-59 £33,800,000,000 £47,600,000,000 £48,700,000,000 
60-64 £27,400,000,000 £39,900,000,000 £45,000,000,000 
65-69 £21,400,000,000 £31,300,000,000 £39,200,000,000 
70-74 £14,400,000,000 £22,400,000,000 £30,100,000,000 
75-79 £7,310,000,000 £13,100,000,000 £18,500,000,000 
80-84 £2,060,000,000 £4,440,000,000 £6,690,000,000 
85-90 £431,000,000 £1,050,000,000 £1,690,000,000 
90+ £27,800,000 £59,900,000 £111,000,000 
Total £506,138,800,000 £560,659,900,000 £547,771,000,000 
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Table 3b 
Females Aggregate Gains (£, 2000 prices)   
Agegroup 1970-1980 1980-1990 1990-2000 
Birth £2,580,000,000 £2,230,000,000 £1,500,000,000 
1-4 £11,700,000,000 £10,100,000,000 £6,820,000,000 
5-9 £17,300,000,000 £15,200,000,000 £10,300,000,000 
10-14 £19,900,000,000 £17,700,000,000 £12,200,000,000 
15-19 £21,400,000,000 £19,300,000,000 £13,300,000,000 
20-24 £23,900,000,000 £21,800,000,000 £15,200,000,000 
25-29 £30,600,000,000 £28,700,000,000 £20,400,000,000 
30-34 £36,400,000,000 £35,600,000,000 £25,900,000,000 
35-39 £37,900,000,000 £38,800,000,000 £29,000,000,000 
40-44 £34,000,000,000 £36,700,000,000 £28,500,000,000 
45-49 £31,100,000,000 £36,100,000,000 £29,200,000,000 
50-54 £32,200,000,000 £40,800,000,000 £35,200,000,000 
55-59 £24,300,000,000 £33,100,000,000 £31,100,000,000 
60-64 £20,700,000,000 £28,600,000,000 £29,700,000,000 
65-69 £18,700,000,000 £25,000,000,000 £27,800,000,000 
70-74 £17,000,000,000 £22,200,000,000 £24,500,000,000 
75-79 £13,600,000,000 £18,400,000,000 £19,100,000,000 
80-84 £6,680,000,000 £9,970,000,000 £9,540,000,000 
85-90 £2,530,000,000 £4,360,000,000 £3,790,000,000 
90+ £317,000,000 £552,000,000 £460,000,000 
Total £402,807,000,000 £445,212,000,000 £373,510,000,000 
 
Table 3c  
 
Aggregate Gains (£, 2000 prices) 
  
 
Total gains (males) £1.61 trillion  
Total gains (females) £1.22 trillion  
TOTAL  £2.84 trillion  
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The economic return arising from improved survival presented above has been 
calculated without consideration of health care expenditure. Of course over the time 
period under consideration there have been improvements in the delivery of health 
care and increased funding of health care delivery throughout the UK. Following the 
approach by Murphy and Topel, the net return associated with improved survival over 
the period is calculated by removing/adjusting for the impact of health care 
expenditure over the same period as 
 
∫∫
∞
−−
∞
−− Δ−−=Δ
a
asr
a
F
asrN dssXsSedssCsSsSeaV )()()()]()([)( *)(12
)( θ   [8] 
 
Where all the terms are defined as above with the exception of  which denotes 
the survival function fixed at year 2000 levels and 
)(* sS
)(sXΔ  which is the increase in real 
expenditures over a given period . The estimate for )(sXΔ , given in 2000 prices, is 
based on the real per capita health care expenditures for the relevant years. These per 
capita figures were given an age profile by adjusting by the age breakdown of per 
capita health care expenditures in 2004 for the age groups 0-4, 5-14, 15-44, 45-64, 65-
74, 75-84 and over 85. Table 4 reports the results and shows that the overall total 
economic gain remains substantial, at £2.58 trillion even after netting out the growth 
in health care expenditures over the period 1970-2000. 
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Table 4 Gains from reduction in mortality by age attributed to increased survival net of 
health care expenditure growth 
 
Table 4a 
Males Aggregate Gains (£, 2000 prices) 
Agegroup 1970-1980 1980-1990 1990-2000 
Birth £2,760,000,000 £2,110,000,000 £824,000,000 
1-4 £12,800,000,000 £9,900,000,000 £4,410,000,000 
5-9 £22,800,000,000 £19,000,000,000 £14,400,000,000 
10-14 £26,400,000,000 £22,400,000,000 £17,500,000,000 
15-19 £27,700,000,000 £23,700,000,000 £18,300,000,000 
20-24 £29,500,000,000 £25,800,000,000 £20,500,000,000 
25-29 £37,100,000,000 £33,400,000,000 £27,300,000,000 
30-34 £44,800,000,000 £42,200,000,000 £35,300,000,000 
35-39 £47,500,000,000 £47,800,000,000 £40,900,000,000 
40-44 £43,500,000,000 £47,300,000,000 £41,300,000,000 
45-49 £39,600,000,000 £47,300,000,000 £41,500,000,000 
50-54 £42,300,000,000 £55,700,000,000 £51,400,000,000 
55-59 £32,300,000,000 £46,100,000,000 £45,800,000,000 
60-64 £26,300,000,000 £38,700,000,000 £42,800,000,000 
65-69 £19,500,000,000 £29,300,000,000 £35,500,000,000 
70-74 £13,300,000,000 £21,200,000,000 £27,800,000,000 
75-79 £6,300,000,000 £12,000,000,000 £16,500,000,000 
80-84 £1,760,000,000 £4,120,000,000 £6,110,000,000 
85-90 £322,000,000 £931,000,000 £1,470,000,000 
90+ £21,700,000 £53,400,000 £99,400,000 
Total £476,563,700,000 £529,014,400,000 £489,713,400,000 
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Table 4b 
Females Aggregate Gains (£, 2000 prices)   
Agegroup 1970-1980 1980-1990 1990-2000 
Birth £1,760,000,000 £1,350,000,000 -£107,000,000 
1-4 £8,230,000,000 £6,470,000,000 £128,000,000 
5-9 £15,900,000,000 £13,700,000,000 £7,600,000,000 
10-14 £18,500,000,000 £16,300,000,000 £9,460,000,000 
15-19 £19,500,000,000 £17,300,000,000 £9,680,000,000 
20-24 £22,100,000,000 £19,900,000,000 £11,700,000,000 
25-29 £28,500,000,000 £26,500,000,000 £16,400,000,000 
30-34 £34,200,000,000 £33,200,000,000 £21,500,000,000 
35-39 £35,700,000,000 £36,500,000,000 £24,900,000,000 
40-44 £32,200,000,000 £34,900,000,000 £25,000,000,000 
45-49 £28,600,000,000 £33,500,000,000 £24,500,000,000 
50-54 £29,700,000,000 £38,200,000,000 £30,500,000,000 
55-59 £22,500,000,000 £31,200,000,000 £27,700,000,000 
60-64 £19,300,000,000 £27,100,000,000 £27,100,000,000 
65-69 £16,100,000,000 £22,300,000,000 £22,700,000,000 
70-74 £15,100,000,000 £20,200,000,000 £20,800,000,000 
75-79 £11,500,000,000 £16,100,000,000 £15,000,000,000 
80-84 £5,810,000,000 £9,050,000,000 £7,850,000,000 
85-90 £2,030,000,000 £3,830,000,000 £2,820,000,000 
90+ £266,000,000 £497,000,000 £360,000,000 
Total £367,496,000,000 £408,097,000,000 £305,591,000,000 
 
Table 4c 
 
Aggregate Gains (£, 2000 prices) 
  
 
Total gains (males) £1.5 trillion  
Total gains (females) £1.08trillion  
TOTAL  £2.58trillion  
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Following Murphy and Topel’s methodology, estimates of the monetarised gains that 
would be established if R&D in medical care gave rise to a further 1%, 10% and 
100% fall in the probability of death from major diseases were obtained. Use of the 
basic approach given in equation [5] and application to the range of diseases defined 
in the tables resulted in the estimates shown in Tables 5, 6 and 7. For a 1% decrease in 
the probability of death from the defined diseases a total of £3,000 million in 
economic welfare would be achieved from such a reduction, with the largest gains 
being achieved through improving life expectancy associated with heart disease and 
cancer. These results are replicated for a 10% decrease and a 100% decrease in the 
relevant probabilities. Focusing on the calculations of a 10% fall in the probability of 
death from major diseases, table 6 shows that the total gain would be £37,000 million 
with heart disease and diseases relating to malignant neoplasms again being the 
largest contributors towards gains. The prospective gain in mortality from heart 
disease being reduced by 10% would be close to £8,000 million. Of course while such 
gains assume no diminishing returns to health investments in these areas, they are 
nevertheless impressive. 
 
Table 5. Prospective gains from a permanent 1% reduction in death rates by major 
cause of death 
 Males Females Total 
All causes 
 
£2,030,877,524 £1,672,899,141 £3,703,776,665 
Infectious and parasitic diseases £11,750,601 £10,029,363 £21,779,964 
Diabetes mellitus £12,777,009 £12,388,204 £25,165,213 
Pneumonia & influenza £89,442,215 £108,440,513 £197,882,728 
Chronic liver disease and cirrhosis £22,699,221 £13,737,527 £36,436,747 
Chronic obstructive pulmonary disease and allied 
conditions 
£62,268,067 £49,121,157 £111,389,224 
Malignant neoplasms £348,751,319 £319,532,484 £668,283,802 
Malignant neoplasm of digestive organs and 
peritoneum digestive organs 
£103,699,269 £74,552,906 £178,252,174 
Malignant neoplasm of trachea, bronchus and lung 
respiratory 
£90,341,273 £54,689,359 £145,030,632 
Malignant neoplasm of female breast Not applicable £64,211,175 £64,211,175 
Malignant neoplasm of genitourinary organs £56,743,386 £48,800,857 £105,544,243 
Major cardiovascular disease £559,535,860 £439,464,320 £999,000,180 
Diseases of the heart £469,229,898 £319,233,242 £788,463,140 
Cerebrovascular disease £82,972,850 £113,666,039 £196,638,889 
Accidents and adverse effects £55,450,025 £24,359,230 £79,809,255 
Motor vehicle traffic accidents £24,146,419 £7,448,706 £31,595,125 
Homicide and injury purposely inflicted by other 
persons 
£2,054,339 £1,118,714 £3,173,053 
Suicides and injury undetermined whether 
accidentally or purposely inflicted 
£39,015,775 £12,105,345 £51,121,120 
 
Note: Sub-categories are not exclusive and therefore do not total to the figures given in major categories 
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Table 6. Prospective gains from a permanent 10% reduction in death rates by major 
cause of death 
 Males Females Total 
All causes 
 
£20,313,861,359 £16,732,088,925 £37,045,950,285 
Infectious and parasitic diseases £115,716,366 £99,084,256 £214,800,622 
Diabetes mellitus £130,030,063 £124,821,863 £254,851,926 
Pneumonia & influenza £896,555,281 £1,085,704,943 £1,982,260,224 
Chronic liver disease and cirrhosis £228,956,475 £136,257,429 £365,213,904 
Chronic obstructive pulmonary disease and 
allied conditions 
£624,002,538 £492,985,476 £1,116,988,014 
Malignant neoplasms £3,489,167,761 £3,194,545,748 £6,683,713,508 
Malignant neoplasm of digestive organs and 
peritoneum digestive organs 
£1,035,944,984 £746,734,911 £1,782,679,895 
Malignant neoplasm of trachea, bronchus and 
lung respiratory 
£903,510,859 £547,508,496 £1,451,019,356 
Malignant neoplasm of female breast not applicable £644,106,359 £644,106,359 
Malignant neoplasm of genitourinary organs £568,762,040 £487,621,167 £1,056,383,207 
Major cardiovascular disease £5,595,604,968 £4,396,739,344 £9,992,344,312 
Diseases of the heart £4,691,439,374 £3,191,307,798 £7,882,747,172 
Cerebrovascular disease £828,305,582 £1,135,153,553 £1,963,459,135 
Accidents and adverse effects £553,175,198 £244,911,322 £798,086,520 
Motor vehicle traffic accidents £241,718,343 £72,890,129 £314,608,472 
Homicide and injury purposely inflicted by other 
persons 
£22,442,942 £11,189,616 £33,632,558 
Suicides and injury undetermined whether 
accidentally or purposely inflicted 
£388,528,585 £120,526,517 £509,055,102 
 
Note: Sub-categories are not exclusive and therefore do not total to the figures given in major categories 
 
 
Table 7. Prospective gains from a permanent 100% reduction in death rates by major 
cause of death 
 
 Males Females Total 
All causes 
 
£203,140,372,839 £167,330,471,615 £370,470,844,454 
Infectious and parasitic diseases £1,156,885,862 £991,046,009 £2,147,931,871 
Diabetes mellitus £1,299,705,279 £1,247,622,327 £2,547,327,606 
Pneumonia & influenza £8,967,261,281 £10,860,054,742 £19,827,316,023 
Chronic liver disease and cirrhosis £2,287,054,105 £1,363,442,507 £3,650,496,612 
Chronic obstructive pulmonary disease and 
allied conditions 
£6,239,521,972 £4,927,746,179 £11,167,268,151 
Malignant neoplasms £34,892,465,117 £31,944,737,630 £66,837,202,747 
Malignant neoplasm of digestive organs 
and peritoneum digestive organs 
£10,357,803,479 £7,468,435,528 £17,826,239,007 
Malignant neoplasm of trachea, bronchus 
and lung respiratory 
£9,033,157,317 £5,476,734,767 £14,509,892,084 
Malignant neoplasm of female breast not applicable £6,441,039,590 £6,441,039,590 
Malignant neoplasm of genitourinary 
organs 
£5,690,157,730 £4,878,605,276 £10,568,763,006 
Major cardiovascular disease £55,957,300,000 £43,971,252,817 £99,928,552,817 
Diseases of the heart £46,914,208,701 £31,912,430,292 £78,826,638,993 
Cerebrovascular disease £8,282,121,199 £11,353,267,008 £19,635,388,207 
Accidents and adverse effects £5,530,400,000 £2,446,200,000 £7,976,600,000 
Motor vehicle traffic accidents £2,419,853,662 £729,772,682 £3,149,626,344 
Homicide and injury purposely inflicted by 
other persons 
£224,949,449 £112,142,201 £337,091,650 
Suicides and injury undetermined whether 
accidentally or purposely inflicted 
£3,887,527,687 £1,205,942,060 £5,093,469,747 
 
Note: Sub-categories are not exclusive and therefore do not total to the figures given in major categories 
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4. Sensitivity analysis 
The general results are of course dependent on to the assumptions made. The basic 
calculation rests on the value of the discount rate, the change in survival probabilities 
seen across the various decades analysed, the value of θ  assumed, which is in turn 
dependent on the value of life assumed and the value of lifetime consumption, which 
itself depends on the proxy values for life cycle earnings. It seems reasonable to 
maintain a discount rate of 3.5% as this is historically low and reflects current 
anticipation of the public sector riskless return. The change in survival probabilities 
cannot reasonably be changed. It is reasonable to assume the value of lifetime 
consumption is not subject to alteration. The value of life however varies markedly 
across different studies even if only UK studies are considered (Viscusi and Alby, 
2003). However, before noting the sensitivity to changes in the value of life, a 
comparison of the UK and US findings as calculated by Murphy and Topel (op.cite.) 
is undertaken to set the context. 
 
Assuming the US population to be approximately 3.5 times as large as the UK 
population, an exchange rate of £1 to $0.54 and that average wages are comparable, 
the crude conversion of the UK findings to US figures suggests a figure of 
approximately $20 trillion as the measure of gain from medical R&D in the UK over 
the period 1970-2000. This is substantially below the Murphy and Topel estimate of 
$46 trillion. It might be argued that demographic structure accounts for some of the 
difference but in fact the UK has a slightly higher proportion of the elderly and lower 
proportion of the young in its population than the USA. In other words the higher 
gains in the US do not reflect substantially different demographics which translate 
into higher improvements in survival probabilities. Nevertheless there is some 
evidence to suggest that the US population may be less healthy than the UK 
population and therefore may have more to gain from R&D investment (Banks, 
2006). In all likelihood however it is the estimate of the value of life used in the 
present study (£1.14 million; approximately $0.6 million) compared to the $5 million 
used by Murphy and Topel which explains the difference across the calculations. The 
value of life provides data necessary to calculate the parameter θ  from equation [3] 
and used in subsequent calculations. In fact when the UK value of life is set at £1.14 
million the value of θ  is 2.84, as compared to a value of θ  of 2.9 calculated by 
 25
Murphy and Topel when using a value of life set at $5 million. As noted in the 
introduction, the estimates of the value of life gained from the UK vary widely and 
the estimates based on compensating differentials are “implausibly large” (Viscusi 
and Abby, 2003). This notwithstanding if the UK value of life is increased to £2.7 
million (approximately $5 million), which is at the higher end of the UK valuations, 
θ  becomes 6.73 and the calculated gain from medical R&D becomes £6.4 trillion 
($12.8 trillion), which when multiplied up to the US population scale gives a close 
approximation to the Murphy and Topel estimate ($44.8 trillion). This increase in the 
value of life is roughly in line with the upper end of UK value of life estimates which 
are gained when individuals are asked about risk of death in direct relation to specific 
diseases, most notably heart disease and cancer (Jones-Lee et al, 1985; Andrews and 
McCrea, 1999). The main point is therefore that amongst other factors the results are 
extremely sensitive to the value of life adopted. The £1.14 million adopted in this 
study reflects the value currently adopted by UK government. Figures 5 and 6 indicate 
the spread of these gains across the UK population from 1970 – 2000 for males and 
females respectively. 
 
Figure 5. Calculated monetary return to increased survival using a value of life of £2.7 
million. Males 
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Figure 6. Calculated monetary return to increased survival using a value of life of £2.7 
million. Females 
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Of course one must be careful in drawing inferences with respect to the monetarised 
gains of reductions in mortality and relating these to the rate of return from medical 
R&D. First all of the caveats concerning the calculations should be borne in mind: in 
particular the inferred gain rests on a number of assumptions relating to the value of 
life, lifecycle consumption and the conversion of R&D into reductions in survival 
probability regardless of gains achieved through changes in life style and 
environment. It is simply incorrect to attribute the full return of improved UK survival 
rates (probability) merely to UK medical R&D given the significant effect of life style 
changes, environmental changes and any spillover benefits gained from R&D 
conducted abroad although the fact that improvements in quality of life have not been 
considered in the analysis is expected to mitigate the bias. 
 
Obviously the annual investment in the UK medical sector is small compared to the 
estimated net gain of £2.58 trillion, albeit that this gain accrued over a 30-year period. 
The investment is less than 1% of the total monetarised gains estimated above. 
Moreover this assumes investments have been at this historically high level, which is 
not the case.  
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5. Conclusions 
 This paper has replicated the work of Murphy and Topel in the UK context at a time 
when there has been increased interest in the return to health sector R&D (UK 
Evaluation Forum, 2006). The results show that even when, in comparison to this 
earlier work, the value of a statistical life is lower in absolute terms and health 
expenditure growth is netted out of the calculations the return to UK medical R&D is 
(can be) inferred to be substantial. This conclusion is reached with fairly rudimentary 
calculations of the monetary return to improved life expectancy. Of course such an 
inference neglects any impact of lifestyle and environment on life expectancy during 
the timeframe considered, but this omission is balanced by focus on mortality to the 
neglect of monetary estimates of the improvements in quality of life attributable to 
medical research over the period. 
 
This paper represents a first attempt to apply the value of life approach with the aim to 
at least provide an indication of the order of magnitude the gains to medical research 
within the UK might be over the period 1970-2000. Buxton et al (2004) attempt to 
calculate the return within the UK context in a different manner which does not easily 
lend itself to aggregation of benefits. This notwithstanding many conceptual issues 
remain unresolved with the present methodology such as the appropriateness of the 
time period considered, how to deal with the issue of externalities, suitable elicitation 
of value of life and not least how to truly net out the impact of R&D alone on 
improvements in life expectancy let alone gains in quality of life. The results suggest, 
with all the caveats above, that the monetarised gains in longeviety equate to 
approximately two years of GDP growth. Such conclusions are preliminary of course 
and much refinement is required before a more precise figure can be put on the actual 
return to medical R&D in the UK. 
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